April 12th 2024
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cross Q&A: Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Experts from the Mayo Clinic and UT Southwestern share insight on the CARTITUDE-4 study and ciltacabtagene autoleucel in the second cross Q&A session.
Relapsed/Refractory Multiple Myeloma: The CARTITUDE-4 Study
Key opinion leader Prashant Kapoor, MD, FACP, shares data from the CARTITUDE-4 study of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.
Cross Q&A: Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma
Panelists follow up with questions and comments on the KarMMa-3 study in relapsed/refractory multiple myeloma and consider how idecabtagene vicleucel might fit into real-world practice.
Non-BCMA Targeting Bispecifics in MM and Future Directions in Care
Before closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.
Relapsed/Refractory Multiple Myeloma: The KarMMa-3 Study
Expert Larry Anderson, Jr, MD, PhD, FACP, reviews data from the KarMMa-3 study of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Team Introductions: MM Experts From UT Southwestern vs Mayo Clinic
Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in relapsed/refractory multiple myeloma.
Emerging BCMA Targeting Bispecifics in Multiple Myeloma
Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.
Supportive Care Strategies for Patients with MM on Bispecifics Treatment
Key opinion leaders consider when it is appropriate to utilize bispecific dose holds or reductions when treating patients with multiple myeloma.
Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM
Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.
Unmet Needs and Future Directions in the Management of Multiple Myeloma
Experts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.